<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972542</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-ENDO4</org_study_id>
    <nct_id>NCT01972542</nct_id>
  </id_info>
  <brief_title>The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk</brief_title>
  <official_title>The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk in Healthy People, Impaired Glucose Tolerance and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypertriglyceridemia at fasting status has been known to be an important risk factor for
      cardiovascular disease (CVD). Recently, postprandial triglyceride (TG) levels draw an
      attention as a superior predictor of CVD because of non-fasting state for more than 12 hours
      and importance of triglyceride-rich lipoprotein.

      We aim to investigate the relationship of postprandial triglyceride after fat tolerance test
      and intima-medial thickness and to suggest normal reference of postprandial triglyceride
      after fat tolerance test. In addition, we evaluate the correlation of postprandial
      triglyceride and incretin secretion after fat tolerance test Ultimately, we want to estimate
      clinical importance of postprandial triglyceride in assessment of cardiovascular risk.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Triglyceride</measure>
    <time_frame>8 hours</time_frame>
    <description>Blood sample : drawn by a catheter before the meal and every 1 hour after meal over the 8-hour period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of incretin</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetes</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 DM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention : Oral fat tolerance test
well or moderately controlled type 2 diabetes mellitus (HbA1c &lt; 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prediabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention : Oral fat tolerance test
Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal glucose tolerance</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intervention : Oral fat tolerance test
No impaired fasting glucose and impaired glucose tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral fat tolerance test</intervention_name>
    <arm_group_label>Type 2 DM</arm_group_label>
    <arm_group_label>Prediabetes</arm_group_label>
    <arm_group_label>Normal glucose tolerance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age : 19 ~ 70 yrs

          -  Type 2 diabetes : HbA1c &lt;10%

          -  Prediabetic state : HbA1c 5.7~6.4%

        Exclusion Criteria:

          -  Type 1 diabetes, secondary diabetes

          -  dipeptidyl peptidase-4 -inhibitor, glucagon-like peptide-1 agonist, thiazolidinediones
             users

          -  Thyroid disease with abnormal thyroid function test

          -  Liver disease with abnormal liver function test

          -  severe kidney disease

          -  pregnant or lactating women

          -  current smoker

          -  severe obesity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim, MD, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Postprandial period</keyword>
  <keyword>triglyceride</keyword>
  <keyword>Diabetes mellitus, type 2</keyword>
  <keyword>Prediabetic state</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

